Drug Trial Radar · NCT06004050
A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema
Last checked: Nov 20, 2026Latest source record: Sep 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
362
Actual
Start
Sep 5, 2023
Primary completion
Dec 16, 2024
Study completion Sep 12, 2025
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- Aug 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the efficacy of twice-daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in the treatment of participants with moderate to severe chronic hand eczema (CHE).
Conditions
- Chronic Hand Eczema
Interventions
DelgocitinibDrug
Topical administration
Vehicle creamOther
Topical administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Investigator Global Assessment for Chronic Hand Eczema Score (IGA-CHE TS) at Week 16Time frame: Week 16
Locations
37 sites in 1 country. Site status is shown where the registry gives one.
LEO Pharma Investigational Site
Beijing, China
LEO Pharma Investigational Site
Beijing, China
LEO Pharma Investigational Site
Beijing, China
LEO Pharma Investigational Site
Beijing, China
LEO Pharma Investigational Site
Changchun, China
LEO Pharma Investigational Site
Changsha, China
LEO Pharma Investigational Site
Changsha, China
LEO Pharma Investigational Site
Changzhou, China
LEO Pharma Investigational Site
Chengdu, China
LEO Pharma Investigational Site
Chengdu, China
LEO Pharma Investigational Site
Fuzhou, China
LEO Pharma Investigational Site
Guangzhou, China
LEO Pharma Investigational Site
Guangzhou, China
LEO Pharma Investigational Site
Guiyang, China
LEO Pharma Investigational Site
Hangzhou, China
LEO Pharma Investigational Site
Hangzhou, China
LEO Pharma Investigational Site
Hangzhou, China
LEO Pharma Investigational Site
Hefei, China
LEO Pharma Investigational Site
Nanchang, China
LEO Pharma Investigational Site
Nanjing, China
LEO Pharma Investigational Site
Nanyang, China
LEO Pharma Investigational Site
Shanghai, China
LEO Pharma Investigational Site
Shenyang, China
LEO Pharma Investigational Site
Shenzhen, China
LEO Pharma Investigational Site
Shenzhen, China
LEO Pharma Investigational Site
Shenzhen, China
LEO Pharma Investigational Site
Shenzhen, China
LEO Pharma Investigational Site
Shijiazhuang, China
LEO Pharma Investigational Site
Wenzhou, China
LEO Pharma Investigational Site
Wuhan, China
LEO Pharma Investigational Site
Wuhan, China
LEO Pharma Investigational Site
Wuhan, China
LEO Pharma Investigational Site
Wuxi, China
LEO Pharma Investigational Site
Xianyang, China
LEO Pharma Investigational Site
Yinchuan, China
LEO Pharma Investigational Site
Yiwu, China
LEO Pharma Investigational Site
Zhenjiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.